Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2024-09-03
Completion Date
2027-06
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
SSGJ-707
bispecific antibody
Bevacizumab
VEGF antibody
Oxaliplatin
chemotherapy
Capecitabine
chemotherapy
Calcium Folinate
chemotherapy
5-fluorouracil
chemotherapy
Locations (1)
Liu Tianshu
Shanghai, Shanghai Municipality, China